Dry-AMD: a new therapeutic hope
A French start-up company plans to revolutionize the treatment of age-related macular degeneration (AMD) with a new generation retinal implant.
160 million people worldwide are affected by dry AMD. 2-5% of all Dry-AMD is Geographic Atrophy which there is currently no treatment available. During the « Journées nationales de la macula » November 23rd to 27th, 2020, Pleine Vie dedicates a piece to Pixium Vision and its Prima system.
Replay of the Key Opinion Leader on the Prima System for dry-AMD
Pixium Vision’s key opinion leader on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD). In case you were unable to attend or would like to hear all or part of it again, the replay of the event is now available online: https://www.pixium-vision.com/KOL-Call-October-2020/
The webinar featured a presentation by José-Alain Sahel, M.D., University of Pittsburgh School of Medicine, Lisa C. Olmos de Koo, M.D., University of Washington and Ralf Hornig, Director of Clinical Affairs, who discussed the current treatment landscape and unmet medical need of Advanced Atrophic dry-AMD. They also shared their experience on how the Prima system is helping their patients regain autonomy and quality of life. Dr Yannick Le Mer and Dr Joseph Martel joined to answer questions following the formal presentation.The Pixium Vision management team also gave an update on the Prima System which has the potential to address this significant unmet medical need in dry-AMD.
Lloyd Diamond Discusses How Pixium Vision is Creating a Solution for Dry Age-Related Macular Degeneration on Neural Implant Podcast
Dry age-related macular degeneration affects millions of people globally. Using an insertable implant in the eye in combination with lenses, central vision focus can be regained. In this episode, Lloyd Diamond discusses how Pixium Vision is creating a solution to dry age-related macular degeneration.
Top three takeaways:
- There is a dry and wet form of age-related macular degeneration. The dry form makes up 80% of all cases.
- The degeneration begins in the center of the eye and then migrates to the periphery at the age of 60-65.
- The implant is no thicker than a human hair and contains 378 independent electrodes on it, activated by light.